Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Purpose

Throughout the Etiologic and Early Marker Studies (EEMS) existence, several studies have measured various immune markers in blood serum. For CDAS, these measurements are available in separate datasets corresponding to each study for which they were originally selected.

Population

These studies were each selected at different time points, using a different set of exclusions and matching criteria. For all studies, the common requirements for inclusion were etiologic consent, pre-diagnostic serum availability, intervention arm, a baseline questionnaire, some form of follow-up within the trial, and no history of the site-specific cancer prior to blood collection. For all non-pilot studies, the set of cases were matched directly to the controls. Matching was done at a 1:1 ratio, except for never-smokers in the lung studies, in which never-smoking controls were matched to never-smoking cases at a 3:1 ratio. The second lung study is a replication of the first using completely different cases and controls. Time on study was not considered in the matching for the NHL and Ovarian studies.

Site Non-Common Inclusion Criteria Matching Variables Cases Non-Cases
Lung Defined Smoking History
  • Gender
  • Age at Randomization (5 Years)
  • Year of Randomization
  • Smoking History
  • Study Year of Dx/Selection
527 592
NHL No Cancer at Baseline
  • Gender
  • Age at Randomization (5 Years)
  • Year of Randomization
  • Study Center
  • Year and Season of Entry (4 Months)
301 301
Ovarian
  • Females
  • Controls Cancer-free through Follow-up
  • No Cancer Prior to DX/Selection
  • No Oophorectomies in Controls
  • Race
  • Age at Randomization (5 Years)
  • Year and Season of Blood Draw (3 Months)
  • Study Year of Blood Draw
  • Time of Day of Blood Draw (am/pm)
150 149
Pilot (controls only)
  • No Cancer at Baseline
  • Cancer-free through Follow-up
  • Confirmed Dead
N/A N/A 100
2nd Pilot (controls only)
  • No Cancer at Baseline
  • Cancer-free through Follow-up
  • Confirmed Dead
  • Not in any EEMS Studies
  • Has Less than 3 Years of Follow-up Time
N/A N/A 54
2nd Lung
  • Defined Smoking History
  • Not in First MIP Lung Study
  • Gender
  • Age at Randomization (5 Years)
  • Year of Blood Draw (2 Years)
  • Study Year of Blood Draw
  • Smoking History
  • Study Year of Dx/Selection
526 625
Endometrial
  • Females
  • No American Indians or Missing Race
  • No Cancer at Baseline
  • Controls Cancer-free through Follow-up
  • No Cancer Prior to DX/Selection
  • No Hysterectomy
  • Race
  • Age at Randomization (5 Years)
  • Fiscal Year of Randomization (2 Years)
  • Study Year of Blood Draw
  • Study Year of Dx/Selection
284 284
Upper GI
  • No Cancer at Baseline
  • Males Only among Gastric Cases
  • Gender
  • Race
  • Age at Blood Draw (+/- 1 Year)
  • Year of Blood Draw
  • Study Year of Blood Draw
  • Time of Day of Blood Draw (am/pm)
  • Number of Days on Study
63 63

Data Collected

Below is a table of the analytes measured in each study. All measures are presented in pg/mL.

  Lung NHL Ovarian Pilot 2nd Pilot 2nd Lung Endometrial Upper GI
Adiponectin X X
Adipsin X X
Amylin X X X X
Basic Fibroblast Growth Factor X X X X X X X X
B-Cell Attracting Chemokine 1 X X X X X X X
C-C motif chemokine ligand 1 X
Chemokine Ligand 10 X X X X X X X X
Chemokine Ligand 11 X X X X X X X
Chemokine Ligand 12 X X X X X X X
Chemokine Ligand 13 X X X X X X X
Chemokine Ligand 19 X X X X X X X
Chemokine Ligand 2 X X X X X X X X
Chemokine Ligand 20 X X X X X X X
Chemokine Ligand 21 X X X X X X X
Chemokine Ligand 22 X X X X X X X X
Chemokine Ligand 27 X X X X X X X
Chemokine Ligand 5 X X X X X X X
Chemokine Ligand 6 X X X X X X X
Chemokine Ligand 7 X X X X X
Chemokine Ligand 8 X X X X X X X
Chemokine Ligand 9 X X X X X X X
C-peptide X X X X
C-Reactive Protein X X X X X X X
C-X3-C motif chemokine ligand 1 X X X X X X
C-X-C motif chemokine ligand 1 X X X X X X X X
Eotaxin X X X X X X X X
Eotaxin-2 X X X X X X X
Eotaxin-3 X
Epidermal Growth Factor X X X X X X X X
Epidermal Growth Factor Receptor X X X X X X X X
Fms-related tyrosine kinase 3 ligand X X X X X
Gastric inhibitory polypeptide X X X X
Ghrelin X
Glucagon X X X X
Glucagon-like peptide-1 X X X X
Granulocyte colony-stimulating factor X X X X X X X X
Granulocyte-macrophage colony-stimulating factor X X X X X
Insulin X X X X
Interferon alpha-2 X X X X X
Interferon-gamma X X X X X
Interleukin 1 X X X X X X X X
Interleukin 1 alpha X X X X X
Interleukin 1 beta X X X X X
Interleukin 1 Receptor Antagonist X X X X X X X
Interleukin 10 X X X X X
Interleukin 11 X X X X
Interleukin 12 p40 X X X X X
Interleukin 12 p70 X X X X X
Interleukin 13 X X
Interleukin 15 X X X X
Interleukin 16 X X X X X X X
Interleukin 17 X X X X X
Interleukin 2 X X X X
Interleukin 20 X
Interleukin 21 X X
Interleukin 23 X X
Interleukin 28 alpha X
Interleukin 29 Interferon Lambda 1 X X X X X X X
Interleukin 3 X X X X X X X
Interleukin 33 X X X X X X X
Interleukin 4 X X X X X
Interleukin 5 X X X X X
Interleukin 6 X X X X X
Interleukin 7 X X X X X X X
Interleukin 8 X X X X X X X X
Interleukin 9 X
Leptin X X X X
Leukemia Inhibitory Factor X X X X
Lipocalin-2 X X
Macrophage colony-stimulating factor X
Macrophage inflammatory protein 1 alpha X X X X X X
Macrophage inflammatory protein 1 beta X X X X X X X X
Macrophage inflammatory protein 1 delta X X X X X X X
Pancreatic Polipeptide X X X X
Pancreatic Polipeptide YY X X X X
Plasminogen activator inhibitor-1 X X
Resistin X X
Serum Amyloid A X X X X X X
Serum Amyloid P X X X X X X
Soluble Interleukin 1 Receptor Type 1 X X X X X
Soluble Interleukin 2 Receptor Alpha X X X X
Soluble Interleukin 4 Receptor X X X X X X X X
Soluble Interleukin 6 beta X X X X X X X X
Soluble Interleukin 6 Receptor X X X X X X X X
Soluble Receptor for Advanced Glycation Endproducts X X X X X
Soluble Tumor Necrosis Factor Receptor I X X X X X X X X
Soluble Tumor Necrosis Factor Receptor II X X X X X X X X
Stem Cell Factor X X X X X X X
Thrombopoietin X X X X X X X
Thymic Stromal Lymphopoietin X X X X X X X
Thymus and Activation Regulated Chemokine X X X X X X X
Transforming Growth Factor Alpha X X X X X X X
Transforming growth factor beta 1 X
Tumor Necrosis Factor Alpha 1 X X X X X X X X
Tumor Necrosis Factor Beta X X X X X X X
Tumor Necrosis Factor Receptor Superfamily, Member 10 X X X X X X X
Tumor Necrosis Factor Receptor Superfamily, Member 5 X X X X X
Tumor Necrosis Factor Receptor Superfamily, Member 8 X X X X X
Vascular Endothelial Growth Factor X X X X X X X X
Vascular endothelial growth factor receptor 1 X X X X X
Vascular endothelial growth factor receptor 2 X X X X X X X X
Vascular endothelial growth factor receptor 3 X X X X X X X X
X-C motif chemokine ligand 1 X

Multiplex Immune Marker Panel Studies data can be obtained in the MIPS datasets

Main Findings